About Altimmune
Altimmune is a publicly listed company based in Gaithersburg (United States) founded in 1997, and was acquired by PharmAthene in January 2017. Vaccines for infectious diseases and solid tumors are developed. Altimmune has raised $58 million across 23 funding rounds from investors including NIH, HHS and U.S Army. The company has 59 employees. Altimmune has completed 1 acquisition, including Immune Targeting Systems. Its chief executive, as recorded, is Vipin K Garg. Its website altimmune.com draws about 209 thousand monthly visits. Its focus areas include Life Sciences, Metabolic Diseases, Drugs and Hepatic disorders. Its competitors include NGM Biopharmaceuticals, Nimbus Therapeutics and Mirum Pharmaceuticals; 3 of its 3 listed competitors have raised funding.
Company details
Altimmune was founded in 1997 and is based in Gaithersburg, United States, within the biotechnology sector. Focus is placed on developing vaccines and immunotherapies targeting infectious diseases like influenza and hepatitis B, alongside treatments for solid tumors and related conditions. Products under development include NasoVAX for intranasal influenza vaccination, HepTcell for chronic hepatitis B, ALT-801 for non-alcoholic steatohepatitis, T-COVID for intranasal COVID-19 therapy, and NasoShield for anthrax protection.
- Headquarters Gaithersburg, United States
- Employees 59
- Stage Acquired
- SectorsHealthcare
- Website category Finance · Investing
- Website altimmune.com
- Social LinkedIn
- Acquired by PharmAthene (Jan 2017)
- Legal Name Altimmune, Inc.
- Annual Revenue$41 K (USD)105as on Dec 31, 2025
- Net Profit-$88.09 M (USD)7.33as on Dec 31, 2025
- EBITDA-$94.38 M (USD)8.31as on Dec 31, 2025
- Total Equity Funding$58M (USD)
in 23 rounds
- Latest Funding Round$4.7M (USD), Grant
Jun 2020
- InvestorsNIH
& 11 more
- Employee Count59
- Investments & Acquisitions
- Acquired byPharmAthene
(Jan 2017)
Funding Insights of Altimmune
Altimmune has successfully raised a total of $58M across 23 strategic funding rounds. The most recent funding activity was a Grant round of $4.7 million completed in June 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $58M
- Total Rounds 23
- Last Round Grant — $4.7M
- First Round $282,625
(Jun 2001)
- Investors Count 11
Latest 10 of 23 funding rounds of Altimmune with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jun 2020 | $4.7M | Grant | – | – | |
| Aug 2019 | $3.7M | Grant | – | – | – |
| Sep 2018 | $24.1M | Grant | – | – | |
| Mar 2015 | $42M | Series B | – | – | – |
| Feb 2015 | $16M | Series B | – | – | |
| Jun 2012 | $110,000 | Grant | – | – | |
| Jun 2012 | $110,701 | Grant | – | – | |
| Dec 2011 | $1M | Grant | – | – | |
| Sep 2011 | $21.7M | Grant | – | – | |
| Sep 2010 | $934,013 | Grant | – | – |
12 investors in total: 12 institutional.
Investors in Altimmune
Altimmune has secured backing from 12 investors, including institutional and venture fund investors. Prominent investors backing the company include NIH, HHS and U.S Army.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Investments are made in innovative life science companies globally. | nvfund.com | Basel, Switzerland | ||
| healthcap.eu | ||||
Truffle Capital is recognized as a leading European venture capital firm. | 2001 | truffle.com | Paris, France | |
PE firm investing in the US | redmontcapital.com | Birmingham, United States | ||
Land-based military forces are organized and deployed for national defense. | 1775 | army.mil | ||
BARDA is focused on developing medical countermeasures for public health security. | medicalcountermeasures.gov | United States | ||
Drug discovery services are provided to the biopharma sector. | 1887 | nih.gov | United States | |
Public health and human services are overseen by HHS. | 1953 | hhs.gov | ||
Animal welfare solutions are promoted through research grants and prizes. | 2008 | michelsonprizeandgrants.org | Culver City, USA | |
| niaid.nih.gov |
Investor details for Altimmune
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Altimmune
39 people are tracked at Altimmune (19 in leadership, 6 in board & advisors, 14 in team); the tracked headcount is 59.
| Name | Role | Group |
|---|---|---|
Vipin K Garg | CEO | Leadership |
Bertrand Georges | Chief Technology Officer | Leadership |
Nicolas Mourier | Vice President, CMC | Leadership |
Christophe Arbet-Engels | Chief Medical Officer | Leadership |
Randy Brown | Vice President Clinical Operations | Leadership |
Scot Roberts | Chief Scientific Officer | Leadership |
Richard Eisenstadt | Chief Financial Officer | Leadership |
Tony Blandin | Vice President, Quality and Compliance Management | Leadership |
Julio Gutierrez M.D. | Senior Medical Director | Leadership |
Karen Smith | Vice President Finance | Leadership |
Aklilu Meshesha | Director Of Financial Reporting | Leadership |
Gina Guiffre | Director Project Finance Control And Government Contracts | Leadership |
Laura Gibbs | Director, Corporate Operations | Leadership |
Bo Li | Senior Director, Drug Product Development | Leadership |
Raymond Jordt | Chief Business Officer | Leadership |
John J. Suschak III | Senior Director, Research And Scientific Affairs | Leadership |
Siavoche Siassi | Vice President, Commercial Strategy And Portfolio Development | Leadership |
Sambath Chung | Senior Director, IT | Leadership |
Sarah Browne | Vice President Clinical Development | Leadership |
Mitchel Sayare | Chairman of the Board | Board & advisors |
19 more people are available in the full profile.
Complete people profiles for Altimmune
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Altimmune
Altimmune is a publicly listed company on the NASDAQ with ticker symbol ALT in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date17 Oct 2005
- Listed onNASDAQ: ALT
- Listed entityAltimmune, Inc.
- Exchange sectorHealth technology
- ISINUS02155H2004
- Share price$2.43 (-5.08% on the day) · 2026-10-13
- Market capitalisation$472.7M
- EPS (diluted, trailing year)$-0.79
- Volume (last session)3,717,587
Financials of Altimmune
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | $41,000 | -$88.1M | -$94.4M |
| 2024 | $20,000 | -$95.1M | -$102.9M |
| 2023 | $426,000 | -$88.5M | -$83.0M |
| 2022 | -$68,000 | -$84.7M | -$87.2M |
| 2021 | $4.4M | -$97.1M | -$84.9M |
Detailed financial statements for Altimmune
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Altimmune
Altimmune has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Immune Targeting Systems.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
T-cell vaccines against mutating viruses are discovered and developed. | its-innovation.com | London, United Kingdom | 2003 | Feb 2015 | •••• |
Complete acquisition details for Altimmune
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Altimmune
6 dated milestones of Altimmune across 23 years, from founding to its latest funding, stage changes and deals.
- Founded Altimmune is founded.
- Funding First funding round of $283K.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Immune Targeting Systems.
- Exit Acquired by PharmAthene.
- Funding Latest funding round, Grant, of $4.7M.
Competitors of Altimmune
Altimmune has 3 listed competitors in our database, 3 of them funded. They include NGM Biopharmaceuticals, Nimbus Therapeutics and Mirum Pharmaceuticals.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| ngmbio.com | 2007 | San Francisco, United States | $358.87M | 225 | Biologics are developed for cardio-metabolic and liver diseases. | |
| nimbustx.com | 2009 | Cambridge, United States | $685M | 81 | Targeted therapeutics for cancer, metabolic, and inflammatory diseases are developed. | |
| mirumpharma.com | 2018 | Menlo Park, United States | $120M | 196 | Small molecule therapeutics are developed for rare diseases treatment. |
Detailed competitors of Altimmune
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Altimmune
The website of Altimmune (altimmune.com) receives about 209.2K visits a month and ranks #314,225 among all websites worldwide, #3,316 in Investing.
- Monthly visits209.2K
▲ 1.9% vs previous month
- Unique visitors15.8K
per month
- Global rank#314,225
among all websites
- Category rank#3,316
Finance · Investing
- Bounce rate19%
- Pages per visit2.7
- Average visit5 min 29 sec
- DevicesDesktop 4% · Mobile 96%
Websites whose visitors overlap most with Altimmune. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| mainstcapital.com | 100% | 43.3K | #979,547 | View details | |
| greenhill.com | 100% | 7.9K | #2,724,551 | View details | |
| alexanderjarvis.com | 97% | 680.7K | #405,744 | View details | |
10xebitda.com | 10xebitda.com | 94% | #637,518 | – | |
 d18rn0p25nwr6d.cloudfront.net | d18rn0p25nwr6d.cloudfront.net | 94% | – | ||
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 11 similar websites and full traffic analytics for Altimmune
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 11 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Top companies in Metabolic Diseases
3 companies that operate in the same segment as Altimmune (Metabolic Diseases) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Satiety induction through digestable gastric balloon introduced via a swallowed capsule | 2009 | Wellesley, Massachusetts, United States | USD 174.04 M | USD 32.11 M | 137 | |
Developer of peptide therapeutics for the treatment of rare genetic deficiencies | 2010 | Boston, Massachusetts, United States | USD 84 M | USD 189.76 M | 283 | |
Developer of small-molecule drugs | 1991 | Los Angeles, California, United States | USD 50 M | USD 348.97 M | 407 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Altimmune
Complete news archive for Altimmune
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Altimmune
Altimmune was founded in 1997 and raised its 1st funding round 4 years after it was founded.
Altimmune is headquartered in Gaithersburg, United States. It is registered at Gaithersburg, Maryland, United States.
Vipin K Garg is the CEO of Altimmune, as recorded in our data.
Altimmune is a funded company, having raised a total of $58M across 23 funding rounds to date. The company's 1st funding round was a Grant of $934.01K, raised on Jun 2001.
Altimmune has 59 employees.
Annual revenue of Altimmune is $41K as on Dec 31, 2025.
Altimmune was founded in 1997 and is based in Gaithersburg, United States, within the biotechnology sector. Focus is placed on developing vaccines and immunotherapies targeting infectious diseases like influenza and hepatitis B, alongside treatments for solid tumors and related conditions. Products under development include NasoVAX for intranasal influenza vaccination, HepTcell for chronic hepatitis B, ALT-801 for non-alcoholic steatohepatitis, T-COVID for intranasal COVID-19 therapy, and NasoShield for anthrax protection.
Altimmune's top competitors include Nimbus Therapeutics, NGM Biopharmaceuticals and Mirum Pharmaceuticals.
Yes, Altimmune is publicly traded on NASDAQ under the ticker symbol ALT.
Altimmune has made 1 acquisition, including Immune Targeting Systems.
Altimmune has 12 investors. Key investors include NIH, HHS, U.S Army, PharmAthene, and Truffle Capital.
Yes. Altimmune was acquired by PharmAthene in January 2017.